Autolus Therapeutics plc (NASDAQ:AUTL) Short Interest Down 6.1% in September

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) saw a significant decline in short interest in the month of September. As of September 15th, there was short interest totalling 10,730,000 shares, a decline of 6.1% from the August 31st total of 11,430,000 shares. Based on an average daily volume of 971,000 shares, the short-interest ratio is presently 11.1 days.

Institutional Trading of Autolus Therapeutics

A number of institutional investors have recently bought and sold shares of AUTL. ProShare Advisors LLC acquired a new position in shares of Autolus Therapeutics during the 2nd quarter worth $43,000. Daiwa Securities Group Inc. lifted its holdings in shares of Autolus Therapeutics by 2,659.7% in the second quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company's stock valued at $55,000 after purchasing an additional 15,293 shares in the last quarter. Bayesian Capital Management LP purchased a new position in shares of Autolus Therapeutics during the 1st quarter worth approximately $100,000. B. Riley Wealth Advisors Inc. acquired a new stake in Autolus Therapeutics during the 1st quarter valued at $108,000. Finally, SG Americas Securities LLC acquired a new position in shares of Autolus Therapeutics in the first quarter worth $127,000. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently commented on AUTL shares. Needham & Company LLC reaffirmed a "buy" rating and set a $9.00 price target on shares of Autolus Therapeutics in a research report on Monday, June 17th. William Blair reissued an "outperform" rating on shares of Autolus Therapeutics in a research report on Monday, June 3rd. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $8.70.

Autolus Therapeutics Price Performance

AUTL remained flat at $3.63 on Monday. The company's stock had a trading volume of 499,226 shares, compared to its average volume of 1,384,065. The stock's 50-day moving average is $4.00 and its 200 day moving average is $4.32. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.55 and a quick ratio of 18.55. The firm has a market cap of $965.71 million, a PE ratio of -3.03 and a beta of 2.05. Autolus Therapeutics has a 12-month low of $2.01 and a 12-month high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.03). On average, research analysts anticipate that Autolus Therapeutics will post -0.84 EPS for the current year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.